Valuation: Amgen Inc.

Market Cap 238B 203B 190B 174B 327B 22,725B 331B 2,249B 877B 11,416B 892B 872B 37,759B P/E 2026 *
27.8x
P/E 2027 * 24.9x
Enterprise Value 279B 239B 224B 205B 384B 26,695B 389B 2,642B 1,030B 13,410B 1,048B 1,025B 44,355B EV / Sales 2026 *
7.17x
EV / Sales 2027 * 6.8x
Free-Float
99.77%
Yield 2026 *
2.3%
Yield 2027 * 2.43%
1 day+0.95%
1 week+5.71%
Current month+13.15%
1 month+16.26%
3 months+28.79%
6 months+17.29%
Current year+34.30%
1 week 361.95
Extreme 361.95
380.3
1 month 329.4
Extreme 329.4
380.3
Current year 271.8
Extreme 271.8
380.3
1 year 230
Extreme 230
380.3
3 years 230
Extreme 230
380.3
5 years 174.58
Extreme 174.58
380.3
10 years 120.65
Extreme 120.65
380.3
Manager TitleAgeSince
Chief Executive Officer 63 30/04/2012
Director of Finance/CFO 62 12/05/2010
Director of Finance/CFO 67 31/12/2019
Director TitleAgeSince
Chairman 63 31/12/2012
Director/Board Member 65 31/12/2011
Director/Board Member 71 31/12/2011
Change 5-day change 1-year change 3-year change Capi.($)
+0.95%+5.71% - - 238B
+0.88%+6.38%+76.40%+126.87% 1,119B
+1.07%+3.80%+50.73%+64.25% 651B
+1.20%+6.21%+25.81%+80.15% 468B
+1.02%+5.77%+43.63%+43.06% 374B
+0.85%+4.07%+24.97%+41.00% 302B
+1.26%+6.81%+2.27%+13.65% 259B
+1.88%+5.81%+49.57%+70.71% 238B
+1.59%+2.09%-17.33%-53.85% 208B
+1.87%+5.61%+27.32%+89.67% 181B
Average +1.26%+5.17%+31.49%+52.83% 422.21B
Weighted average by Cap. +1.13%+5.40%+44.26%+72.42%

Financials

2026 *2027 *
Net sales 38.94B 33.36B 31.21B 28.57B 53.62B 3,726B 54.32B 369B 144B 1,872B 146B 143B 6,190B 40.2B 34.43B 32.22B 29.49B 55.35B 3,846B 56.08B 381B 148B 1,932B 151B 148B 6,390B
Net income 8.6B 7.36B 6.89B 6.31B 11.84B 823B 11.99B 81.41B 31.75B 413B 32.28B 31.58B 1,367B 9.39B 8.05B 7.53B 6.89B 12.93B 899B 13.11B 88.95B 34.69B 451B 35.27B 34.5B 1,493B
Net Debt 41.49B 35.54B 33.25B 30.44B 57.12B 3,969B 57.88B 393B 153B 1,994B 156B 152B 6,595B 35.83B 30.69B 28.72B 26.29B 49.33B 3,428B 49.98B 339B 132B 1,722B 135B 132B 5,696B
Logo Amgen Inc.
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (95.8%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other 4.2%): primarily royalties. The United States account for 71.9% of net sales.
Employees
31,500
Date Price Change Volume
21/08/26 €376.45 +0.95% 239
20/08/26 €372.90 -0.86% 976
19/08/26 €376.15 +2.90% 289
18/08/26 €365.55 +1.29% 103
17/08/26 €360.90 +1.35% 164
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
34
Last Close Price
439.33USD
Average target price
388.48USD
Spread / Average Target
-11.57%

Quarterly revenue - Rate of surprise